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ERK1/2Pharmacological modulation of tumor radiosensitivity is a promising strategy for enhancing the outcome of
radiotherapy. cAMP signaling plays an essential role in modulating the proliferation and apoptosis of different
cell types, including cancer cells. Until now, the regulation of this pathway was restricted to the transmembrane
class of adenylyl cyclases. In the present study, the role of an alternative source of cAMP, the intracellular localized
soluble adenylyl cyclase (sAC), in the radiosensitivity of prostate cancer cells was investigated. Pharmacological
inhibition of sAC activity led tomarked suppression of proliferation, lactate dehydrogenase release, and induction
of apoptosis. The combination of ionizing radiation with partial suppression of sAC activity (~50%) immediately
after irradiation synergistically inhibited proliferation and induced apoptosis. Overexpression of sAC in normal
prostate epithelial PNT2 cells increased the cAMP content and accelerated cell proliferation under control
conditions. The effects of radiation were signiﬁcantly reduced in transformed PNT2 cells compared with control
cells. Analysis of the underlying cellularmechanisms of sAC-induced radioresistance revealed the sAC-dependent
activation of B-Raf/ERK1/2 signaling. In agreement with this ﬁnding, inhibition of ERK1/2 in prostate cancer cells
enhanced the cytotoxic effect of irradiation. In conclusion, the present study suggests that sAC-dependent
signaling plays an important role in the radioresistance of prostate cancer cells. This article is part of a Special
Issue entitled: The role of soluble adenylyl cyclase in health and disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer remains the most commonly diagnosed malignancy
and the second leading cause of cancer-related deaths in men [1]. The
current standard of care consists of prostatectomy and radiation
therapy, which may often be supplemented with hormonal therapies.
However, nearly 30% of patients experienced relapse at the irradiation
sites [2]. The resistance of prostate cancer to radiotherapy has prompted
a search for new methods of treatment, such as a combination of
radiotherapy with the targeting of certain molecular mechanisms
responsible for the radioresistance of prostate cancer.
In particular, many anti-tumor strategies focus on suppressing the
cell cycle or inducing apoptosis. Within several signaling pathways,
cAMP-dependent signaling plays a substantial role in controlling cell
proliferation and apoptosis. However, the speciﬁc effects of cAMPe of soluble adenylyl cyclase in
vascular Research, Charité-
Berlin, Germany. Tel.: +49 234signaling on proliferation and apoptosis are controversial. For example,
the elevation of cellular cAMP content by stimulating G protein-
responsive transmembrane adenylyl cyclases (tmAC) or by treatment
with cAMP analogs has been shown to either induce or suppress prolif-
eration in different cell types [3–6]. Similarly, cAMP signaling has
conﬂicting effects on apoptosis [7–10]. This discrepancy may be due to
differences in cell types or experimental models. Alternatively, the
lack of speciﬁcity of methods to affect the cAMP signaling, e.g. forskolin,
cAMP analogs or PKA inhibitors, used inmajority of studies, may also be
a cause for this discrepancy. Indeed, overproduction of cAMP by tmAC
due to treatmentwith forskolin unlikely will lead to selective activation
of plasmalemma-localized targets.
Traditionally, cAMP signaling was thought to rely solely on the
production of cAMP at the plasma membrane by tmAC. However,
work by many groups, including our own, has changed this view.
tmAC can continue to signal within the cell following internalization,
thereby deﬁning endocytic cAMP microdomains [11,12]. Furthermore,
a second source of cAMP, type 10 soluble adenylyl cyclase (sAC), has
been identiﬁed in mammalian cells [13]. sAC, unlike tmAC, possesses
no transmembrane domains and is localized throughout the cell in the
cytosol, nucleus, mitochondria, and centriole [14]. Several studies dem-
onstrated the unique activation of sAC by bicarbonate and bivalent
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organs, such as sperm and neutrophils as well as the brain, kidney,
eye, and pancreas [15]. Furthermore, recent studies have demonstrated
that sAC regulates oxidative phosphorylation in mitochondria [16] and
activates the mitochondrial pathway of apoptosis [17].
The role of the sAC-dependent cAMP pool in proliferation control
was unknown. Our recent study demonstrates that sAC promotes pros-
tate cancer cell proliferation in an EPAC-dependent manner [18]. Other
studies have also suggested that nuclear sAC expression is associated
with the transition of keratinocytes and melanocytes from benign cells
into cancers, such as squamous cell carcinoma of the skin and melano-
ma [19,20]. A recent report by Onodera et al. [21] also demonstrated
the involvement of sAC/EPAC signaling in the proliferation of breast
cancer cells. Altogether, these observations suggest that sAC plays a
role in proliferation of some cancer cells and may contribute to the
tumor malignancy. We therefore hypothesized that the inhibition of
sAC could be effective for potentiation of the radiation-induced cytotox-
icity. To test this hypothesis, we utilized humanprostate carcinoma cells
and investigated the anti-proliferative, cytotoxic and pro-apoptotic ef-
fects of a combined treatment including sAC inhibition and irradiation.
2. Material and methods
2.1. Cell culture
Androgen-sensitive LNCaP (ATCC-Nr. CRL-1740D) and androgen-
insensitive PC3 (ATCC-Nr. CRL-1435D) human prostate carcinoma cell
lines were purchased from the American Type Culture Collection, and
the normal human prostate epithelial cell line PNT2 was purchased
from Sigma-Aldrich (Cat. Nr. 95012613). Cells were expanded and
frozen in aliquots within 4 weeks of purchase. For the experiments in
this study, the cells were thawed and cultured for nomore than 3 addi-
tional passages. The LNCaP and PC3 cells were cultured in Dulbecco's
modiﬁed Eagle's medium that was supplemented with 5% fetal calf
serum, 100 U/mL penicillin, and 100 μg/μL streptomycin. PNT2 cells
were cultured in RPMI-1640 medium that was supplemented with
10% fetal calf serum, 100 U/mL penicillin, and 100 μg/μL streptomycin.
The cells were seeded in culture medium containing 2% fetal calf
serum (LNCaP and PC3) or 5% fetal calf serum (PNT2) 12–18 h prior to
each experiment.
2.2. Experimental protocols
U0126 (Cell Signaling), KH7 (Cayman) or its inactive analog, KH7.15
(kindly provided by Dr. J. Buck, Cornell University, NY), was applied to
the cells throughout the duration of the experiment as indicated. At
the end of the experiments, the ﬂoating cells were collected and
combined with the attached cells for further analyses.
2.3. Radiation treatment
The cells were irradiated with 250 keV X-rays (16 mA) produced by
a Müller RT250 (Philips Industrial X-Ray) at a dose rate of 1.5 Gy/min.
The cells were returned to an incubator after the irradiation procedure
and maintained at 37 °C and 5% CO2 until further use.
2.4. sAC overexpression
The cloning of the untargeted expression of sAC, i.e., predominantly
in the cytosol, was performed as previously described [22]. Brieﬂy, the
human inﬂuenza hemagglutinin (HA)-tagged rat sAC gene constructs
were generated by PCR, digested with AgeI and NotI, and cloned into
the eukaryotic expression vector pTurbo-G418 (Evrogen-Axxora). The
plasmids encoding sAC or control vector (donated by Dr. Giovanni
Manfredi, Weill Cornell Medical College, NY) were transfected using
Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) and thenincubated for 24 h. sAC expression in the transfected cells was analyzed
using western blotting and antibodies against sAC.
2.5. Western blotting
The cells were lysed in Laemmli buffer containing 2% SDS, 10%
glycerol, 0.1% 2-mercaptoethanol, 0.002% bromophenol blue, and
0.0625 mol/L Tris–HCl. The protein concentrations were determined
using the Pierce 660 nm Protein Assay Reagent combined with the
Ionic Detergent Compatibility Reagent (Thermo Scientiﬁc). Equal
amounts of total proteins were separated on SDS-polyacrylamide gels
and transferred to a nitrocellulose membrane. The utilized primary an-
tibodies were as follows: sAC (clone R21, kindly provided by Dr. J. Buck,
Cornell University, NY), actin (Chemicon International), cleaved
caspase-3, phos-B-Raf, B-Raf, phos-ERK, and ERK1/2 (Cell Signaling).
After incubation with peroxidase-linked and horseradish peroxidase-
labeled secondary antibodies, speciﬁc bands were visualized by chemi-
luminescence using the ECLPlus Kit (Amersham Pharmacia). Equivalent
sample loading (10–30 μg/well) was conﬁrmed by stripping the
membranes with Restore Western Blot Stripping Buffer (Pierce) prior
to incubating the membranes with antibodies against actin.
2.6. Rap1 activity assay
The level of activated Rap1was determined using a pull-down assay
kit (Jena Bioscience, Jena, Germany), which is based on glutathione
S-transferase fusion to the Ras-binding domain of RalGDS, following
the manufacturer's instructions. The amounts of GTP-bound Rap1 and
total Rap1 were determined by western blotting followed by staining
with an anti-Rap1A antibody.
2.7. Analysis of cell number
After staining with 4% trypan blue (Gibco), trypan blue-negative
cells were counted using a Neubauer hemocytometer (depth: 0.1 mm).
2.8. Cellular cAMP analysis
Analysis of the total cellular cAMP content was performed using the
cAMP (direct) enzyme immunoassay kit (Assay Designs). The prepara-
tion of cell extracts and cAMPmeasurementswere performed following
the manufacturer's protocol. The absorbance measured at 405 nm was
used to calculate the concentration of cAMP by applying a calibration
curve.
2.9. FACS-based subG1-population analysis
The cellswereﬁxedwith 70% alcohol, stainedwith propidium iodide
and treated with RNase (BD Biosciences, Heidelberg, Germany), which
was followed by DNA content analysis using a FACSCalibur ﬂow
cytometer (BD Biosciences).
2.10. Analysis of lactate dehydrogenase in the culture medium
Lactate dehydrogenase (LDH) activity in the cell culture medium
was used as an indicator of necrosis and was determined using the Cy-
totoxicity Detection Kit (Roche Applied Science). After each experiment,
the culturemediumwas centrifuged at 500 ×g for 5min at 4 °C, and the
supernatant was subjected to LDH analysis using an ELISA reader.
2.11. Statistical analysis
The data are presented as the mean ± SEM. Comparisons of the
means of the groups were performed using one-way analysis of vari-
ance followed by the post hoc Bonferroni test. P b 0.05 was considered
statistically signiﬁcant.
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3.1. Effect of irradiation on proliferation and cell death
To examine the resistance to irradiation, two human prostate
carcinoma cell lines were initially utilized: LNCaP and PC3. First, the
dose- and time-dependent effects of irradiation on proliferation and
cell death were investigated. We found that irradiation of cells with a
total dose of 10 Gy (1.5 Gy/min) led to suppression of proliferation
within 24 h accompanied by a signiﬁcant increase in the subG1 popula-
tion (apoptosis), cleavage of caspase-3, and LDH release (necrosis) after
48 and 60 h (Supplementary Fig. 1). The effects observed at 48 h after
irradiation were dose-dependent; i.e., a gradual suppression of prolifer-
ation and increase in LDH release and apoptosis were noted as the
irradiation dose increased from 5 to 15 Gy (Supplementary Fig. 2). A
comparison of the irradiation effects between LNCaP and PC3 cells re-
vealed the higher radioresistance of LNCaP cells, especially in respect
to irradiation-induced cytotoxicity and apoptosis. Therefore, this cell
line was used for further analyses. Examination of cellular cAMP content
in LNCaP cells did not reveal any signiﬁcant alteration after irradiation
(mean ± SEM, n = 5, pmol/mg proteins): 5.81 ± 0.41 at 0 Gy, 5.23 ±
0.33 at 5 Gy, 7.02 ± 0.31 at 10 Gy and 6.02 ± 0.43 at 15 Gy.cA
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Fig. 1. Inhibition of sAC suppresses the proliferation and leads to the death of prostate cancer c
number per dish, and lactate dehydrogenase (LDH) activity in the cell culture medium (presen
treated with the sAC inhibitor KH7 (0–30 μmol/L, black symbols) or its inactive analog KH7.15
beginning of all experiments. The values are presented as themean± SEM (n= 3–12). *P b 0.0
cell lysates. The treatment conditions are similar to those described for (A). The data are repre3.2. Effect of sAC inhibition
To examine the role of sAC in proliferation and cell death, LNCaP cells
were treated for 48 h with the speciﬁc sAC inhibitor KH7 at doses of 10,
20, and 30 μmol/L. Previous studies demonstrated that KH7 inhibits sAC
in various cell types over a concentration range of 10–30 μmol/L,
whereas it has no effect on tmAC and soluble guanylyl cyclase at
concentrations up to 100 μmol/L [23]. We found that KH7 dose-
dependently suppressed the cellular cAMP content with a maximal
effect at 20 μmol/L (Fig. 1A). KH7 treatment had a similar dose-
dependent effect on cell proliferation and death (Fig. 1B–D). To further
rule out possible nonspeciﬁc, sAC-independent effects of KH7, an inac-
tive analog of KH7, KH7.15 [24], was utilized in these experiments.
In contrast to KH7, KH7.15 did not affect the cellular cAMP content,
proliferation, or cell death (Fig. 1).
3.3. Effect of irradiation in combination with sAC inhibition
To test whether inhibition of sAC may support the cytotoxic and
anti-proliferative effects of irradiation, treatment with the sAC inhibitor
KH7 was applied immediately after irradiation. In these experiments,
KH7 was applied at 10 μmol/L, which causes only partial suppressionC
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sentative of four independent experiments with similar results.
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Furthermore, a submaximal dose of irradiation, 5 Gy, was applied. We
found that irradiation at a dose of 5 Gy led to suppression of prolifera-
tion and promoted a level of cytotoxicity that was comparable with
that of partial sAC inhibition via treatment with 10 μmol/L KH7
(Fig. 2). Combining irradiation at 5 Gy with sAC inhibition signiﬁcantly
increased the anti-proliferative and cytotoxic effects of irradiation,
which were signiﬁcantly stronger than that of irradiation at 10 Gy
(Fig. 2A, B). Similarly, the inhibition of sAC signiﬁcantly enhanced the
pro-apoptotic effect of irradiation (Fig. 2C). In contrast to KH7, treat-
ment with inactive analog, i.e., KH7.15, had no effects on proliferation,
LDH release and caspase-3 cleavage (Fig. 2).3.4. Overexpression of sAC increases radioresistance
To further substantiate the role of sAC in radioresistance the overex-
pression of sAC was performed in PNT2 cells. This LNCaP-relevant, non-
tumor prostate epithelial cell line showed markedly low expression of
sAC and a low proliferation rate compared to LNCaP cells, although
this difference in proliferation may not be necessary due to differences
of sAC expression (Fig. 3A). In line with these data, overexpression of
sAC signiﬁcantly increased cAMP content and the proliferation rate
(Fig. 3B, C). By applying irradiation at a dose of 10 Gy, we found that
the sAC overexpression signiﬁcantly increased the radioresistance of
PNT2 cells, i.e., a higher cell number and lower LDH release were
found 48 h after irradiation in sAC-overexpressed cells compared with
the control (Fig. 3C, D). In fact, irradiation of cells transfected with sAC
vector reduced the cell number to 76 ± 7%, whereas in cells transfected
with control vector the cell number was reduced to 55± 5% (P b 0.05).
Furthermore, sAC expression suppressed irradiation-induced caspase-3
cleavage (Fig. 3E).
To additionally prove the role of sAC in radioresistance in sAC over-
expressing PNT2 cells, inhibition of sAC in these cells with KH7 has beenCleaved
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Fig. 2. Inhibition of sAC increases the radiosensitivity of prostate cancer cells. (A, B) Statistical an
culturemedium (presented as a ratio of the individual protein content, relative units) performe
incubation of cells without orwith the sAC inhibitor KH7 (10 μmol/L) or its inactive analog KH7
vs. Control. §P b 0.05 vs. KH7, 5 Gy and 10 Gy. (C) Western blot analysis of cleaved caspase-3
described for (A) and (B). The data are representative of three independent experiments withapplied. The sAC inhibition abolished the effect of sAC overexpression
(Fig. 3C, D, E).3.5. Importance of sAC/B-Raf/ERK signaling in radioresistance
Because the EPAC/Rap1 pathwaywas found to be responsible for the
control of sAC-dependent proliferation [18], we examined whether the
anti-proliferative effect of sAC inhibition in the present studywas due to
downregulation of MAP kinase signaling, which is downstream of the
EPAC/Rap-1 pathway. An analysis of B-Raf and ERK1/2 demonstrated
that the phosphorylated forms of these proteins were downregulated
after 12 h of sAC inhibition and were associated with the downregula-
tion of GTP-bound Rap1 (Fig. 4A). In contrast, treatment with an inac-
tive analog of KH7, i.e., with KH7.15 had no effects on ERK1/2
phosphorylation (Supplementary Fig. 3). Because the ERK1/2 signaling
supports radioresistance of various tumors [25,26], we hypothesized
that this signaling may be a primary downstream pathway responsible
for the sAC-dependent radioresistance of LNCaP cells. To prove this
hypothesis, we examined the effects of ERK1/2 on the irradiation effects
in LNCaP cells. Treatment with U0126, a highly selective inhibitor of
upstream MEK1/2, suppressed ERK1/2 phosphorylation/activation in
control as well as irradiated cells (Fig. 4B). In support of our hypothesis,
inhibition of ERK1/2 signiﬁcantly enhanced the anti-proliferative and
cytotoxic effects of irradiation (Fig. 4C).4. Discussion
The purpose of the present study was to determine whether sAC
plays a role in the resistance of prostate carcinoma cells to irradiation.
The main ﬁndings are as follows: (i) Inhibition of sAC enhanced the
radiosensitivity of LNCaP tumor cells. In contrast, the overexpression
of sAC in non-tumor PNT2 cells promotes radioresistance. (ii) ERK1/2B
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radioresistance.
cAMP signaling regulates diverse cell functions, including cell death
and growth. However, traditionally, cAMP synthesis was solely attribut-
ed to the G protein-coupled tmAC; therefore, it was restricted to the
plasmalemma. Our reports demonstrated that an alternative source of
cAMP, intracellular sAC, plays a key role in apoptosis induced by ischemia,
acidosis, or oxysterols in several cell types [17,27,28]. Furthermore, recent
studies also emphasized the role of sAC in promoting the proliferation
of prostate carcinoma and breast cancer cells [18,21]. These data
suggest that sAC may be a promising target for improving radiotherapy
outcomes.Utilizing LNCaP cells, we examined the contribution of sAC in
radioresistance by applying pharmacological inhibition of sAC immedi-
ately after irradiation. Because sAC activity plays a role in several
physiological cell functions [15], complete suppression of sAC may be
detrimental to non-tumor cells. Thus, in these experiments, we partially
suppressed sAC (by approximately 50%). Under these conditions, the
anti-proliferative, cytotoxic, and pro-apoptotic effects of irradiation at
5 Gywere signiﬁcantly increased. Importantly, these effects were stron-
ger than those observed with irradiation at the higher dose (10 Gy).
To further emphasize the contribution of sAC in radioresistance, an
opposite approach, i.e., sAC overexpression, was applied in non-tumor
PNT2 cells. Interestingly, these untreated cells showed a signiﬁcantly
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Fig. 4. ERK1/2 is a key downstream target responsible for the sAC-dependent radioresistance of LNCaP cells. (A) Western blot analysis of the active form of Rap-1 (Rap-1-GTP) and the
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four independent experiments with similar results. (B) Western blot analysis of the phosphorylated form of ERK1/2 performed with lysates of control LNCaP cells or cells treated with
irradiation (5 Gy) followed by treatment for 48 h with 10 μmol/L MEK1/2 inhibitor (U0126) as indicated. Western blot data are representative of three to four independent experiments
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when targeted expression of sAC was applied, a signiﬁcant rise in the
proliferation rate could be observed that was comparable with that of
LNCaP cells. Furthermore, these transformed cells showed a signiﬁcant-
ly higher radioresistance compared to the scrambled control. Therefore,
both approaches, which manipulate sAC signaling, argue for a key role
of sAC in radioresistance.
The mechanisms responsible for the anti-proliferative, cytotoxic,
and pro-apoptotic effects of sAC inhibition appear to be different from
those induced by ionizing radiation. Indeed, radiation suppresses cell
growth due to DNA damage by indirect (formation of oxygen radicals)
or direct (double-strand breaks followed by the DNA damage response
and cell cycle arrest) actions [29,30]. In a previous study, we found that
the inhibition of sAC suppresses proliferation due to downregulation
of the EPAC/Rap-1 pathway [18]. In contrast to non-tumor PNT2 cells,
sAC is overexpressed in tumor LNCaP cells (Fig. 3A); similarly, sAC is
overexpressed in human prostate carcinoma comparedwith benign hy-
perplasia [18]. Such overexpression upregulates EPAC/Rap-1 signaling
and may lead to overactivation of the downstream MAP kinase
pathway. Indeed, the present study revealed that suppression of sAC
reduced the phosphorylation of B-Raf and ERK1/2 kinases, which are
downstream of the EPAC/Rap-1 axis. The activity of MAP kinases,particularly of the ERK1/2 kinases, has been shown to be responsible
for the radioresistance of various cancer cells [25,26]. In agreement
with these studies, suppression of ERK1/2 phosphorylation in our
study signiﬁcantly enhanced the radiosensitivity of prostate cancer
cells. Therefore, ERK1/2 seems to be a key downstream target responsi-
ble for sAC-dependent radioresistance. Although the role of EPAC
in proliferation and oncogenesis has been demonstrated in various
models [3–5,21], the possible contribution of EPAC signaling in
the radioresistance of tumor cells remains weakly understood. One
recent study [31] suggests the inhibitory role of EPAC in the repair of
irradiation-induced DNA damage. However, only the contribution
of the membrane-bound adenylyl cyclase (forskolin treatment) was
examined in this study.
In contrast to EPAC, numerous reports have emphasized the role of
PKA, the second major target for cAMP, in the radioresistance of cancer
cells. Indeed, PKA has been shown to support the radioresistance of
prostate cancer cells [32]. Moreover, PKA overexpression is correlated
with prostate cancer patient outcomes after radiotherapy [33]. In con-
trast to these reports, PKA has also been shown to promote apoptosis
due to phosphorylation of the prostate apoptosis response-4 protein
[34]. Similarly, activation of PKA by treatmentwith a speciﬁc agonist en-
hances the radiosensitivity of prostate cancer cells [35]. Although the
2662 A. Appukuttan et al. / Biochimica et Biophysica Acta 1842 (2014) 2656–2663role of PKA in the radiosensitivity of prostate cancer cells is still contro-
versial, PKA signiﬁcantly contributes in radiation outcome. Neverthe-
less, PKA is unlikely to play a role in sAC-dependent radioresistance in
our study. Indeed, our previous reports demonstrated that the sAC/
PKAaxis promotes apoptosis rather than proliferation [27,28]. Addition-
ally, the direct inhibition or activation of PKA in LNCaP cells has no effect
on proliferation [18].
In conclusion, the present study describes a novel signaling that
contributes to the radioresistance of prostate cancer cells. Suppression
of the sAC-speciﬁc cAMP pool, leading to inhibition of B-Raf/ERK signal-
ing, signiﬁcantly enhances the anti-proliferative and cytotoxic effects of
irradiation. Further analysis of the sAC-dependent pathways in other
radioresistant tumors may have a potential clinical signiﬁcance. Partic-
ularly, one recent study [19] supposes the role of sAC in squamous cell
carcinoma, which belongs to radioresistant tumors.
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